Data from the ALIGN trial, where the endothelin A receptor antagonist atrasentan effectively reduced proteinuria [50], were similar to the project where the molecular expression of endothelin 1 was correlated with the risk of IgA nephropathy progression [38], so we think that our observed endothelin 1 correlation in this disease is connected with the results of the treatment, not real pathogenic effects. This evidence concerns the gene EDN1 and IgA glomerulonephritis.